BCR-ABL is an unregulated kinase produced by a genetic mutation and it causes most cases of chronic myeloid leukemia. Scientists developed a treatment based on the structure of BCR-ABL. The drug, called Gleevec, physically blocks the binding pocket of BCR-ABL and prevents its unregulated activity. Additional genetic mutations result in Gleevec-resistant forms of cancer.
This Click and Learn supports the 2013 Holiday Lectures on Science. It provides an example of how advances in molecular biology, structural biology, and DNA sequencing have revolutionized the treatment of certain types of cancer.
Download the accompanying worksheet (PDF) to guide students through their exploration of this Click and Learn.